© 2004 by European Society of Cardiology
Copyright © 2004, European Society of Cardiology
Review of aldosterone- and angiotensin II-induced target organ damage and prevention
Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Tayside DD1 9SY, Dundee, UK
* Corresponding author. Tel.: +44-1382-632574; fax: +44-1382-644972. a.d.struthers{at}dundee.ac.uk
Aldosterone is well recognized as a cause of sodium reabsorption, water retention, and potassium and magnesium loss; however, it also produces a variety of other actions that lead to progressive target organ damage in the heart, vasculature, and kidneys. Aldosterone interacts with mineralocorticoid receptors to promote endothelial dysfunction, facilitate thrombosis, reduce vascular compliance, impair baroreceptor function, and cause myocardial and vascular fibrosis. Although angiotensin II has been considered the major mediator of cardiovascular damage, increasing evidence suggests that aldosterone may mediate and exacerbate the damaging effects of angiotensin II. While angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers reduce plasma aldosterone levels initially, aldosterone rebound, or ‘escape’ may occur during long-term therapy. Therefore, aldosterone blockade is required to reduce the risk of progressive target organ damage in patients with hypertension and heart failure. This may be achieved nonselectively with spironolactone or with use of the selective aldosterone blocker eplerenone. While both agents have been demonstrated to be effective antihypertensive agents, eplerenone may produce improved target organ protection as witnessed in a variety of clinical settings, without the antiandrogenic and progestational effects commonly observed with spironolactone.
KEYWORDS Heart failure; Target organ damage; Aldosterone; Angiotensin II; Spironolactone; Eplerenone
Time for primary review 20 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Nakamura, K. Kataoka, M. Fukuda, H. Nako, Y. Tokutomi, Y.-F. Dong, H. Ichijo, H. Ogawa, and S. Kim-Mitsuyama Critical Role of Apoptosis Signal-Regulating Kinase 1 in Aldosterone/Salt-Induced Cardiac Inflammation and Fibrosis Hypertension, September 1, 2009; 54(3): 544 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. A. Delou, A. G. Lopes, and M. A.M. Capella Unveiling the Role of Multidrug Resistance Proteins in Hypertension Hypertension, August 1, 2009; 54(2): 210 - 216. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Martin-Fernandez, M.ķa Miana, N. De las Heras, G. Ruiz-Hurtado, M.ķa Fernandez-Velasco, M. Bas, S. Ballesteros, V. Lahera, V. Cachofeiro, and C. Delgado Cardiac L-type calcium current is increased in a model of hyperaldosteronism in the rat Exp Physiol, June 1, 2009; 94(6): 675 - 683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Fang, D. G. Oreopoulos, and J. M. Bargman Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3704 - 3710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Pitt The measurement of plasma aldosterone in patients post-myocardial infarction Eur. Heart J., October 2, 2008; 29(20): 2451 - 2452. [Full Text] [PDF]
|
|
|
|
 |
|
 A.C. Montezano, G.E. Callera, A. Yogi, Y. He, R.C. Tostes, G. He, E.L. Schiffrin, and R.M. Touyz Aldosterone and Angiotensin II Synergistically Stimulate Migration in Vascular Smooth Muscle Cells Through c-Src-Regulated Redox-Sensitive RhoA Pathways Arterioscler Thromb Vasc Biol, August 1, 2008; 28(8): 1511 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fischer, R. Dechend, F. Qadri, M. Markovic, S. Feldt, F. Herse, J.-K. Park, A. Gapelyuk, I. Schwarz, U. B. Zacharzowsky, et al. Dietary n-3 Polyunsaturated Fatty Acids and Direct Renin Inhibition Improve Electrical Remodeling in a Model of High Human Renin Hypertension Hypertension, February 1, 2008; 51(2): 540 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Henke, R. Schmidt-Ullrich, R. Dechend, J.-K. Park, F. Qadri, M. Wellner, M. Obst, V. Gross, R. Dietz, F. C. Luft, et al. Vascular Endothelial Cell Specific NF-{kappa}B Suppression Attenuates Hypertension-Induced Renal Damage Circ. Res., August 3, 2007; 101(3): 268 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Collins, G. Rosano, C. Casey, C. Daly, M. Gambacciani, P. Hadji, R. Kaaja, T. Mikkola, S. Palacios, R. Preston, et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists Eur. Heart J., August 2, 2007; 28(16): 2028 - 2040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fischer, R. Dechend, A. Gapelyuk, E. Shagdarsuren, K. Gruner, A. Gruner, P. Gratze, F. Qadri, M. Wellner, A. Fiebeler, et al. Angiotensin II-induced sudden arrhythmic death and electrical remodeling Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1242 - H1253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Inagaki, F. Otsuka, J. Suzuki, Y. Kano, M. Takeda, T. Miyoshi, H. Otani, Y. Mimura, T. Ogura, and H. Makino Involvement of Bone Morphogenetic Protein-6 in Differential Regulation of Aldosterone Production by Angiotensin II and Potassium in Human Adrenocortical Cells Endocrinology, June 1, 2006; 147(6): 2681 - 2689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hunyady and K. J. Catt Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II Mol. Endocrinol., May 1, 2006; 20(5): 953 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Buss, J. Backs, M. M. Kreusser, S. E. Hardt, C. Maser-Gluth, H. A. Katus, and M. Haass Spironolactone Preserves Cardiac Norepinephrine Reuptake in Salt-Sensitive Dahl Rats Endocrinology, May 1, 2006; 147(5): 2526 - 2534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Covic, P. Gusbeth-Tatomir, and D. J. A. Goldsmith Is it time for spironolactone therapy in dialysis patients? Nephrol. Dial. Transplant., April 1, 2006; 21(4): 854 - 858. [Full Text] [PDF]
|
|
|
|
 |
|
 N. C Shah, S. Pringle, and A. Struthers Aldosterone Blockade Over and Above ACE-Inhibitors in Patients with Coronary Artery Disease but without Heart Failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1): 20 - 30. [Abstract] [PDF]
|
|
|
|
 |
|
 W. H. W. Tang, A. C. Parameswaran, A. P. Maroo, and G. S. Francis Aldosterone Receptor Antagonists in the Medical Management of Chronic Heart Failure Mayo Clin. Proc., December 1, 2005; 80(12): 1623 - 1630. [Abstract] [PDF]
|
|
|
|
|
|
R. M.A. van de Wal, D. J. van Veldhuisen, W. H. van Gilst, and A. A. Voors Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? Eur. Heart J., November 2, 2005; 26(22): 2361 - 2367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-J. Min, M. Mogi, J.-M. Li, J. Iwanami, M. Iwai, and M. Horiuchi Aldosterone and Angiotensin II Synergistically Induce Mitogenic Response in Vascular Smooth Muscle Cells Circ. Res., September 2, 2005; 97(5): 434 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fraccarollo, P. Galuppo, I. Schmidt, G. Ertl, and J. Bauersachs Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction Cardiovasc Res, July 1, 2005; 67(1): 97 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Blanco-Rivero, V. Cachofeiro, V. Lahera, R. Aras-Lopez, I. Marquez-Rodas, M. Salaices, F. E. Xavier, M. Ferrer, and G. Balfagon Participation of Prostacyclin in Endothelial Dysfunction Induced by Aldosterone in Normotensive and Hypertensive Rats Hypertension, July 1, 2005; 46(1): 107 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Francis and W.H. W. Tang Should we consider aldosterone as the primary screening target for preventing cardiovascular events? J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1249 - 1250. [Full Text] [PDF]
|
|
|
|
|
|
P. Agostoni, A. Magini, D. Andreini, M. Contini, A. Apostolo, M. Bussotti, G. Cattadori, and P. Palermo Spironolactone improves lung diffusion in chronic heart failure Eur. Heart J., January 2, 2005; 26(2): 159 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Garcia-Dorado, K.-D. Schluter, E. A. Martinson, and H. M. Piper Which papers are most interesting to the readers of Cardiovascular Research? Information from download monitoring Cardiovasc Res, January 1, 2005; 65(1): 1 - 5. [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Haddy, R. Kleta, K. O'Brien, A. A. Syed, C. P.F. Redfern, J. U. Weaver, R. S. Vasan, E. J. Benjamin, D. Levy, R. G. Dluhy, et al. Aldosterone Revisited N. Engl. J. Med., November 11, 2004; 351(20): 2131 - 2133. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Garnier, J. K. Bendall, S. Fuchs, B. Escoubet, F. Rochais, J. Hoerter, J. Nehme, M.-L. Ambroisine, N. De Angelis, G. Morineau, et al. Cardiac Specific Increase in Aldosterone Production Induces Coronary Dysfunction in Aldosterone Synthase-Transgenic Mice Circulation, September 28, 2004; 110(13): 1819 - 1825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Diez Profibrotic Effects of Angiotensin II in the Heart: A Matter of Mediators Hypertension, June 1, 2004; 43(6): 1164 - 1165. [Full Text] [PDF]
|
|